Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how ...

From severe cases of common diseases to rare disorders such as necrolytic migratory erythema, bullous pemphigoid and Darier’s disease, the series offers a closer look at the treatment and ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

such as Dupixent for the treatment of adults with chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron’s ...

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia ... thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural ...

IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate ... obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against ...